May 14, 2008 -- Simcere Pharmaceutical Group (NYSE: SCR) received SFDA approval for a first-to-market generic Biapenem injection, an antibiotic that it will market under the brand name Anxin. Biapenem is a member of the carbenicillin family, and it will compete in the marketplace against brand-name drugs such as Tienam from Merck (NYSE: MRK) and Mepem from Sumitomo Pharmaceuticals. Carbenicillins are used in patients who have developed resistance to other antibiotics. More details...
